BPC-157 / TB-500 FRAG

A large research vial mixing equal weights of BPC-157 and TB-500, two lab-made peptides studied mainly in animals for tissue repair. The 'FRAG' TB-500 is the same 7-amino-acid molecule as the catalog's TB-500.

The pairing combines two separate lines of animal tissue-repair research: BPC-157's effects on blood-vessel growth and nitric oxide, and TB-500's actin binding, studied in cell migration. Because the ratio is fixed, neither peptide can be studied or varied on its own.

No human study has tested the two together, and no animal study of the combination was identified. The closest is a retrospective knee-pain report of four patients who received BPC-157 with full-length thymosin beta-4, a different molecule from TB-500. BPC-157 alone has a few small, uncontrolled human reports; TB-500 has none. The pairing reflects community practice rather than a studied combination.

An FDA adverse-event report describes skin and gum darkening that recurred on re-exposure to a research BPC-157/TB-500 blend; it can't be pinned on either peptide. Both components promote blood-vessel growth or cell migration in animals, and BPC-157 shifted clotting tests and liver enzymes in animal toxicity studies. FDA's immune-reaction warning for research-grade peptides applies to both.

No approved product contains either peptide. Both were removed from FDA's Category 2 list in April 2026, and in July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8–6–1 for each to recommend 503A bulks listing; the votes are advisory, FDA had issued no final rule as of October 2026, and they concern pharmacy compounding for patients, not research-grade material. WADA prohibits both at all times (BPC-157 under S0, TB-500 under S2).